Verve falls after early-stage data for lead asset [Seeking Alpha]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Seeking Alpha
VERVE-101 from patients with a form of dyslipidemia called heterozygous familial hypercholesterolemia (HeFH). Citing a data cut of 10 patients on October 16, Verve ( VERV ) said VERVE-101, an in vivo base editor, at the highest dose level, led up to a 55% decline in low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol. However, out of nine patients who were part of the safety analysis, there were treatment-related adverse events in the two higher-dose groups. Notably, two patients developed serious adverse events, including a myocardial infarction, which was potentially related to treatment, according to the company. The ongoing phase 1b trial called heart-1 is designed to evaluate four dose levels of VERVE-101 in adults living with HeFH and other heart-related conditions such as high cholesterol. However, the company plans to continue patient enrollment "based on favorable initial findings." Recently, Beam Therapeutics ( BEAM ) agreed to sell certain righ
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat ConditionsPR Newswire
- Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual MeetingGlobeNewswire
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 12/11/25 - Form 8-K
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- BEAM's page on the SEC website